Physician profile
Mark A Berk
NPI 1235196858
$4,445.28
in general payments reported to CMS, 2019-2025
27 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,759 · 2020: $524 · 2021: $255 · 2022: $587 · 2023: $873 · 2024: $267 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.18 |
| Education | $265.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,923.60 | 2019-2023 | Xeomin |
| Abbvie INC. | $647.18 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $473.16 | 2019-2024 | Tremfya |
| Amgen INC. | $245.12 | 2019-2023 | Otezla |
| Regeneron Healthcare Solutions, INC. | $173.60 | 2021-2022 | |
| Pfizer INC. | $160.73 | 2019-2021 | |
| Journey Medical Corporation | $142.49 | 2023 | |
| Ucb, INC. | $123.50 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $105.15 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $82.28 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $59.75 | 2019-2021 | |
| Celgene Corporation | $39.70 | 2019 | |
| Sun Pharmaceutical Industries INC. | $35.14 | 2019-2020 | |
| Sebela Pharmaceuticals INC. | $25.76 | 2019 | |
| Genzyme Corporation | $24.14 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $21.37 | 2025 | Sofdra |
| Incyte Corporation | $19.71 | 2024 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.80 | 2019 | |
| Mayne Pharma Commercial LLC | $18.35 | 2020 | |
| Strata Skin Sciences, INC. | $17.70 | 2024 | Xtrac |
| Genentech USA, INC. | $17.48 | 2022 | |
| Sensus Healthcare, INC. | $15.55 | 2019 | |
| Smith+Nephew, INC. | $15.31 | 2020 | |
| Encore Dermatology INC. | $13.49 | 2019 | |
| Mission Pharmacal Company | $12.92 | 2019 | |
| Epi Health, LLC | $11.86 | 2021 | |
| Organon LLC | $1.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Berk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.